Enanta Pharmaceuticals (ENTA) Current Assets (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Current Assets data on file, last reported at $178.4 million in Q1 2026.

• Quarterly Current Assets fell 26.54% year-over-year to $178.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.4 million (down 26.54% YoY) and the FY2025 annual result came in at $204.3 million, down 31.85% from the prior year.
• Current Assets fell to $178.4 million in Q1 2026, from $198.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $448.5 million in Q2 2023 to a low of $178.4 million in Q1 2026.
• A 5-year average of $296.2 million and a median of $286.6 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets surged 43.26% — and 2024, when it sank 36.1%.
• Tracing ENTA's Current Assets over 5 years: stood at $283.7 million in 2022, then soared by 37.57% to $390.3 million in 2023, then slumped by 31.3% to $268.1 million in 2024, then fell by 25.9% to $198.7 million in 2025, then declined by 10.2% to $178.4 million in 2026.
• The last three Current Assets figures came in at $178.4 million (Q1 2026), $198.7 million (Q4 2025), and $204.3 million (Q3 2025), per Business Quant data.